Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.
Here’s what was new in the world of medical device suppliers during the week of April 22.
Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.
Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.
Jan Medical partners with U.S. Army to nab a concussion detection indication for BrainPulse technology.
Biocompatibility of medical devices is a complex and evolving subject. Here's what you need to know.
Toxicologists offer their perspectives on the future of testing.
MD&M Minneapolis speakers point out potential sources of extractables and leachables to consider.